BioAdaptives, Inc. (OTC: BDPT) announced the upcoming commercial launch of XcellaraHeart, a cardiovascular wellness supplement scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August. The product combines the company’s Xcellara stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root.
The Xcellara base formula is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology.
According to the company, XcellaraHeart is designed around a two-part cardiovascular wellness strategy combining stem/progenitor cell mobilization with cardiovascular signaling support. A scientific evidence dossier detailing the formulation is available on the company’s product website at products.xcellara.com/science.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. More information is available at products.xcellara.com.
The complete scientific evidence dossier for the XcellaraHeart formulation separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two. For more information, visit www.bioadaptives.com.
The launch of XcellaraHeart represents a potential advancement in cardiovascular wellness, leveraging clinical evidence and traditional botanical research. The product aims to support cardiovascular repair biology through a dual mechanism, which may appeal to consumers seeking science-based nutritional supplements.
